PubRank

Leon J Thal

Author PubWeight™ 110.21‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005 12.04
2 Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement 2005 7.90
3 High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008 7.35
4 The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am 2005 7.26
5 Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003 6.34
6 Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004 4.66
7 Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008 2.25
8 Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol 2005 1.91
9 Aberrant patterning of neuromuscular synapses in choline acetyltransferase-deficient mice. J Neurosci 2003 1.75
10 DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. Hum Mol Genet 2006 1.73
11 ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord 2006 1.70
12 Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci 2002 1.69
13 Verbal paired-associate learning by APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response. Neurobiol Aging 2006 1.58
14 A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003 1.58
15 Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol 2007 1.57
16 Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging 2007 1.57
17 Identification of Alzheimer disease risk by functional magnetic resonance imaging. Arch Neurol 2005 1.55
18 What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain 2006 1.51
19 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Hum Brain Mapp 2010 1.40
20 Disparate letter and semantic category fluency deficits in autopsy-confirmed frontotemporal dementia and Alzheimer's disease. Neuropsychology 2007 1.37
21 Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009 1.34
22 Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry 2002 1.23
23 Hippocampal volume is associated with memory but not monmemory cognitive performance in patients with mild cognitive impairment. J Mol Neurosci 2003 1.22
24 Decline in verbal memory during preclinical Alzheimer's disease: examination of the effect of APOE genotype. J Int Neuropsychol Soc 2002 1.21
25 Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia. J Neurol 2008 1.18
26 The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. J Sleep Res 2003 1.15
27 Choline transporter 1 maintains cholinergic function in choline acetyltransferase haploinsufficiency. J Neurosci 2004 1.14
28 Progressive impairment on neuropsychological tasks in a longitudinal study of preclinical Alzheimer's disease. Neuropsychology 2007 1.13
29 Utility of the telephone interview for cognitive status for enrollment in clinical trials. Alzheimers Dement 2006 1.10
30 Nerve growth factor promotes survival of new neurons in the adult hippocampus. Neurobiol Dis 2006 1.09
31 ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly. Alzheimer Dis Assoc Disord 2006 1.08
32 Reliability of monitoring the clinical dementia rating in multicenter clinical trials. Alzheimer Dis Assoc Disord 2004 1.07
33 Altered p59Fyn kinase expression accompanies disease progression in Alzheimer's disease: implications for its functional role. Neurobiol Aging 2005 1.06
34 Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol Neurodegener 2007 1.04
35 Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease. Hum Mol Genet 2007 1.03
36 Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies. Neuropsychology 2008 1.03
37 A comparison of episodic memory deficits in neuropathologically-confirmed Dementia with Lewy bodies and Alzheimer's disease. J Int Neuropsychol Soc 2004 0.97
38 Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease. Neuroreport 2002 0.94
39 Emergent psychopathology in Alzheimer's disease patients over 12 months associated with functional, not cognitive, changes. J Geriatr Psychiatry Neurol 2002 0.94
40 Executive dysfunction in Alzheimer disease. Arch Neurol 2004 0.94
41 Lesions of the nucleus basalis magnocellularis induced by 192 IgG-saporin block memory enhancement with posttraining norepinephrine in the basolateral amygdala. Proc Natl Acad Sci U S A 2002 0.93
42 Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach. J Neuropsychiatry Clin Neurosci 2005 0.92
43 Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis. Free Radic Biol Med 2002 0.92
44 Cognitive discrepancies versus APOE genotype as predictors of cognitive decline in normal-functioning elderly individuals: a longitudinal study. Am J Geriatr Psychiatry 2008 0.90
45 Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials. Alzheimer Dis Assoc Disord 2006 0.88
46 Neuropsychological deficits associated with Alzheimer's disease in the very-old: discrepancies in raw vs. standardized scores. J Int Neuropsychol Soc 2003 0.86
47 Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr Alzheimer Res 2008 0.86
48 Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned? Alzheimers Dement 2006 0.86
49 ADCS Prevention Instrument Project: development of a brief verbal memory test for primary prevention clinical trials. Alzheimer Dis Assoc Disord 2006 0.85
50 Mnemonic deficits in animals depend upon the degree of cholinergic deficit and task complexity. Exp Neurol 2002 0.85
51 Estimating the prevalence of agitation in community-dwelling persons with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2002 0.83
52 APOE genotype predicts depression in women with Alzheimer's disease: a retrospective study. Int J Geriatr Psychiatry 2008 0.83
53 Investigating emergent symptomatology as an outcome measure in a behavioral study of Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2002 0.83
54 The septohippocampal cholinergic system and spatial working memory in the Morris water maze. Behav Brain Res 2005 0.82
55 NSAIDs and hypertension. Arch Intern Med 2003 0.81
56 Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer's disease. J Geriatr Psychiatry Neurol 2003 0.80
57 A phase I study of AIT-082 in healthy elderly volunteers. J Mol Neurosci 2002 0.79
58 Density of the brain, decline of the mind: an atypical case of Fahr disease. Arch Neurol 2007 0.79
59 Assessing Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory: scoring and clinical implications. J Psychiatr Res 2001 0.78
60 Growth factor gene therapy for Alzheimer disease. Neurosurg Focus 2002 0.78
61 Regulatable acetylcholine-producing fibroblasts enhance cognitive performance. Mol Ther 2005 0.78
62 Regression to the mean: implications for clinical trials of psychotropic agents in dementia. Curr Alzheimer Res 2004 0.78
63 Modulation of sensory inputs and ectopic presence of Schwann cells depend upon the route and duration of nerve growth factor administration. Exp Neurol 2002 0.78
64 No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients. J Geriatr Psychiatry Neurol 2002 0.77
65 Common threads in neurodegenerative disorders of aging. Alzheimers Dement 2006 0.76
66 How to define treatment success using cholinesterase inhibitors. Int J Geriatr Psychiatry 2002 0.76
67 Long-term production of choline acetyltransferase in the CNS after transplantation of fibroblasts modified with a regulatable vector. Brain Res Mol Brain Res 2004 0.75
68 Toward optimal health: Leon J. Thal, M.D. discusses the latest in Alzheimer's disease in women. Interview by Jodi R. Godfrey. J Womens Health (Larchmt) 2006 0.75
69 Robert Katzman honored. Alzheimer Dis Assoc Disord 2006 0.75